The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 335:696-700 September 5, 1996 Number 10
NextNext

Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip Replacement
David Bergqvist, Ph.D., Göran Benoni, M.D., Ola Björgell, M.D., Hans Fredin, Ph.D., Urban Hedlundh, M.D., Sylvain Nicolas, Ph.D., Paul Nilsson, Ph.D., and Göran Nylander, Ph.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background The risk of venous thromboembolism in patients undergoing total hip replacement is known to be high. However, the optimal duration of prophylaxis with anticoagulant agents after this procedure is unknown. We sought to determine whether one month of anticoagulant therapy with the low-molecular-weight heparin enoxaparin is more effective than enoxaparin therapy given only during the hospitalization for surgery.

Methods Two hundred sixty-two patients undergoing total hip replacement received enoxaparin during their hospitalizations (average stay, 10 to 11 days). They were then randomly assigned to receive enoxaparin or placebo (131 patients each). Blinded outpatient therapy (or placebo) was continued long enough that the total treatment period, inpatient plus outpatient, was one month for each patient. Bilateral ascending phlebography was performed 19 to 23 days after discharge, with deep-vein thrombosis as the primary end point. Distal and proximal thrombosis, pulmonary embolism, and hemorrhage were also recorded, as were deaths.

Results Venography was adequate in 116 patients in the placebo group and 117 in the enoxaparin group. We observed 43 episodes of deep-vein thrombosis and 2 episodes of pulmonary embolism in the placebo group, but only 21 episodes of deep-vein thrombosis and no episodes of pulmonary embolism in the enoxaparin group (incidence of thromboembolism, 39 percent and 18 percent, respectively; P<0.001). The difference in the incidence of proximal deep-vein thrombosis was also significant (24 percent and 7 percent in the placebo and enoxaparin groups, respectively; P<0.001). Six patients in the enoxaparin group and one patient in the placebo group had hematomas at their injection sites. No patients died or had major complications.

Conclusions There were significantly fewer venous thromboembolic complications in patients undergoing elective hip replacement when prophylaxis with enoxaparin was given for a total of one month, rather than only during the hospitalization.


Source Information

From the Department of Surgery, Academic Hospital, Uppsala, Sweden (D.B.); the Departments of Orthopedic Surgery (G.B., H.F., U.H.) and Diagnostic Radiology (O.B., P.N., G.N.), Malmö University Hospital, Malmö, Sweden; and the Department of Research and Development, Rhône–Poulenc Rorer, Paris (S.N.).

Address reprint requests to Dr. Bergqvist at Academic Hospital, Department of Surgery, S-751 85 Uppsala, Sweden.

Full Text of this Article


Related Letters:

Enoxaparin as Prophylaxis against Thromboembolism after Total Hip Replacement
Anderson D. R., Gross M., Robinson K. S., Wells P. S., Pedell L., Bergqvist D.
Extract | Full Text  
N Engl J Med 1997; 336:585-586, Feb 20, 1997. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.